Zai Lab and argenx Report Positive Topline Data from ADHERE

Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG...

Related Keywords

China , Cambridge , Cambridgeshire , United Kingdom , Huashan , Henan , Taiwan , Shanghai , Hong Kong , Macau , United States , Christine Chiou , Alina Zhang , Harald Reinhart , Demyelinating Polyneuropathy , Shaun Maccoun Xiaoyu Chen , Department Of Neurology , Exchange Commission , Zai Lab , Head Of Global Development , Zai Lab Forward , Zai Lab Limited , Huashan Hospital Affiliated To Fudan University , Group Of Huashan Rare Disease Center , Greater China , Chongbo Zhao , Deputy Director , Huashan Hospital Affiliated , Fudan University , Working Group , Huashan Rare Disease , Global Development , Infectious Diseases , Inflammatory Neuropathy Cause , Disability Score , Inflammatory Rasch Built Overall Disability Scale , Private Securities Litigation Reform Act , Nasdaq Zlab ,